<SEC-DOCUMENT>0001193125-18-062171.txt : 20180228
<SEC-HEADER>0001193125-18-062171.hdr.sgml : 20180228
<ACCEPTANCE-DATETIME>20180228080203
ACCESSION NUMBER:		0001193125-18-062171
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20180228
DATE AS OF CHANGE:		20180228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-210792
		FILM NUMBER:		18648104

	BUSINESS ADDRESS:	
		STREET 1:		30930 RUSSELL RANCH ROAD
		STREET 2:		SUITE 301
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362
		BUSINESS PHONE:		818-661-5000

	MAIL ADDRESS:	
		STREET 1:		30930 RUSSELL RANCH ROAD
		STREET 2:		SUITE 301
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d502389d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-210792 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
April&nbsp;27, 2016) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g502389g38c99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$50,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a
Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales Agreement, or sales agreement, with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.01 par value per share,
offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, from time to time we may offer and sell shares of our common stock having an aggregate gross sales price of up to
$50.0&nbsp;million through Cantor Fitzgerald, acting as sales agent, pursuant to this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common
stock is listed on The Nasdaq Global Market under the symbol &#147;MNKD.&#148; On February&nbsp;23, 2018, the last reported sale price of our common stock as reported on The Nasdaq Global Market was $3.04 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an &#147;at the market offering&#148; as defined in Rule
415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Subject to terms of the sales agreement, Cantor Fitzgerald is not required to sell any specific number or dollar amounts of securities but will act as our
sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cantor Fitzgerald and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will be entitled to a commission of up to 3.0% of the gross sales price per share sold under the sales agreement. In
connection with the sale of our common stock on our behalf, Cantor Fitzgerald will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting
commissions or discounts. We have also agreed to provide indemnification and contributions to Cantor Fitzgerald against certain civil liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading
&#147;Risk Factors&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-4</FONT> of this prospectus supplement, and under similar headings in the documents that are incorporated by reference into this prospectus supplement and the accompanying
prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement and the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g502389g71g62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is February&nbsp;28, 2018 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom502389_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_1">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_3">THE SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_4">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_10">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_15">INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to an offering of our common stock. Before buying any of the common stock that we are
offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the headings &#147;Where You Can Find More Information&#148; and
&#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement. These documents contain important information that you should consider when making your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, references in this prospectus supplement and the accompanying prospectus to &#147;MannKind,&#148; the
&#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MannKind Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is
this prospectus supplement, which describes the terms of this offering of common stock and also adds to, updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is the
accompanying prospectus, which gives more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent the information contained in this prospectus supplement differs from
or conflicts with the information contained in the accompanying prospectus or any document incorporated by reference, the information in this prospectus supplement will control. If any statement in one of these documents is inconsistent with a
statement in another document having a later date&#151;for example, a document incorporated by reference into this prospectus supplement and the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes
the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the sales agent has not, authorized anyone to provide you with information different from that which is contained
in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. No one is making offers to sell or seeking offers to buy
these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only and that
any information we have incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document incorporated by reference or as of the date of the prospectus, as applicable, regardless of the time
of delivery of this prospectus supplement, the accompanying prospectus, any related free writing prospectus, or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since those dates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus
and the information incorporated herein and therein by reference include trademarks, servicemarks and tradenames owned by us or other companies. Afrezza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, MedTone<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Dreamboat<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Technosphere<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks in the United States. We have
also applied for other trademark registrations and have registered company trademarks in other jurisdictions, including Europe and Japan. All trademarks, servicemarks and tradenames included or incorporated by reference in this prospectus supplement
or the accompanying prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us and this offering and selected information contained elsewhere in or incorporated by reference into
this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of
our company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus
supplement and the accompanying prospectus, and the information included in any free writing prospectus that we authorize for use in connection with this offering, including the information contained in and incorporated by reference under the
heading &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-4</FONT> of this prospectus supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into
this prospectus supplement and the accompanying prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension. Our only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration in June&nbsp;of 2014 to improve glycemic control in adult patients with diabetes.
Afrezza became available by prescription in United States retail pharmacies in February 2015.&nbsp;According to the Centers for Disease Control and Prevention, 30.3&nbsp;million people in the United States had diabetes in 2015. Globally, the
International Diabetes Federation has estimated that approximately 425.0&nbsp;million people had diabetes in 2017 and approximately 629.0&nbsp;million people will have diabetes by 2045. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Afrezza is a rapid-acting inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder
formulation of human insulin delivered from a small portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and delivers insulin quickly to the bloodstream. The first measurable effects of
Afrezza occur approximately 12 minutes after administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also believe our Technosphere formulations of active pharmaceutical ingredients have the
potential to demonstrate clinical advantages over existing therapeutic options in a variety of therapeutic areas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in the State of Delaware on February&nbsp;14, 1991. Our principal executive offices are located at 30930 Russell Ranch Road, Suite 301,
Westlake Village, California 91362, and our telephone number at that address is (818) <FONT STYLE="white-space:nowrap">661-5000.</FONT> MannKind Corporation and the MannKind Corporation logo are our service marks. Our website address is
http://www.mannkindcorp.com. The information contained in, and that can be accessed through, our website is not incorporated into and does not form a part of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock offered by us</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Shares of our common stock having an aggregate offering price of up to $50,000,000.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Manner of offering</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#147;At the market offering&#148; that may be made from time to time through our sales agent, Cantor Fitzgerald. See &#147;Plan of Distribution&#148; on page <FONT STYLE="white-space:nowrap">S-9</FONT> of this prospectus
supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">We intend to use the net proceeds from this offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses, sales and marketing expenses, general and
administrative expenses, and other expenses associated with the commercialization of Afrezza, any other product candidate we develop and our Technosphere drug delivery platform. See &#147;Use of Proceeds&#148; on page
<FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk Factors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Investing in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under the heading &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-4</FONT> of this
prospectus supplement, in the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and any free writing prospectus that we authorize for use in connection with this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nasdaq Global Market symbol</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#147;MNKD&#148;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. You should carefully consider the risks described below and discussed under the section
captioned &#147;Risk Factors&#148; contained in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, which is incorporated by reference in this prospectus supplement, and all other
information contained in this prospectus supplement and the accompanying prospectus and incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in
connection with this offering, before purchasing shares of our common stock. These risks and uncertainties are not the only ones facing us. Additional risks and uncertainties that we are unaware of, or that we currently deem immaterial, also may
become important factors that affect us. If any of such risks or the risks described below or in our SEC filings occur, our business, financial condition or results of operations could be materially and adversely affected. In that case, the trading
price of our common stock could decline, and you may lose some or all of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have not designated the amount of net proceeds from this offering to be used for any particular purpose, our management will have broad discretion
as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Our management may use the net proceeds for corporate purposes that may not improve our
financial condition or market value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You may experience immediate and substantial dilution. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming
that an aggregate of 16,447,368 shares of our common stock are sold at a price of $3.04 per share pursuant to this prospectus supplement, which was the last reported sale price of our common stock on the Nasdaq Global Market on February&nbsp;23,
2018, for aggregate gross proceeds of $50.0&nbsp;million, after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $4.27 per share, representing the difference between our as
adjusted net tangible book deficit per share as of December&nbsp;31, 2017 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options and warrants may result in further dilution of your investment.
See &#147;Dilution&#148; in this prospectus supplement for a more detailed illustration of the dilution you would incur if you participate in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You may experience future dilution as a result of future equity offerings. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for
our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by any investors in this
offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable
into common stock, in future transactions may be higher or lower than the price per share paid by any investors in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein, contain statements
that are not strictly historical in nature and are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act. These forward-looking statements are subject to the &#147;safe harbor&#148; created by Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act and may include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully market, commercialize and achieve market acceptance for Afrezza or any other product candidates or therapies that we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture sufficient quantities of Afrezza and obtain insulin supply as needed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize our Technosphere drug delivery platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates for future performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and amount of our future recognition of deferred product sales from collaboration, product costs from collaboration and income from collaboration; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress or success of our research, development and clinical programs, including the application for and receipt of regulatory clearances and approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific studies and the conclusions we draw from them; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms under which this offering may be conducted and our anticipated use of proceeds from this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148;
&#147;estimates,&#148; &#147;expects,&#148; &#147;goal,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; the
negative of these words and words or similar expressions intended to identify forward-looking statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and
subject to risks and uncertainties. The underlying information and expectations are likely to change over time. Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ
materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#147;Risk Factors&#148; in this prospectus supplement, in the accompanying prospectus, and in
our filings with the Securities and Exchange Commission, or SEC. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should understand that our actual future results may be materially different from what we expect. In addition, statements that &#147;we believe&#148; and
similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statements were made, and while we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and you are cautioned not to unduly rely upon these statements. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. Unless required by law, we undertake no obligation to
update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such
forward-looking statements. Before deciding to purchase shares of our common stock, you should carefully consider the risk factors discussed or incorporated by reference herein, in addition to the other information set forth in this prospectus
supplement, the accompanying prospectus and in the documents incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $50.0&nbsp;million from time to time. Because there is no minimum
offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully
utilize the sales agreement with Cantor Fitzgerald as a source of financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for general corporate
purposes, including manufacturing expenses, clinical trial expenses, research and development expenses, sales and marketing expenses, general and administrative expenses, and other expenses associated with the commercialization of Afrezza, any other
product candidate we develop and our Technosphere drug delivery platform. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies. Although we have no specific agreements, commitments
or understandings with respect to any acquisition, we evaluate acquisition opportunities and engage in related discussions with other companies from time to time.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the proceeds, if any, from this offering.
Accordingly, we will retain broad discretion over the use of any such proceeds. Pending the use of the net proceeds, from this offering as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_6"></A>DILUTION </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public
offering price per share and the as adjusted net tangible book deficit per share of our common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book deficit
as of December&nbsp;31, 2017 was approximately $(214.7) million, or $(1.80) per share. We calculate net tangible book value (deficit) per share by dividing the net tangible book value (deficit), which is tangible assets less total liabilities, by
the number of outstanding shares of our common stock. Dilution represents the difference between the portion of the amount per share paid by purchasers of shares in this offering and the as adjusted net tangible book deficit per share of our common
stock immediately after giving effect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the assumed sale by us of shares of our common stock in the aggregate
amount of $50.0&nbsp;million in this offering at an assumed offering price of $3.04 per share, which was the last reported sale price of our common stock on the Nasdaq Global Market on February&nbsp;23, 2018, and after deducting commissions and
estimated aggregate offering expenses payable by us, our as adjusted net tangible book deficit as of December&nbsp;31, 2017 would have been approximately $(166.3) million, or $(1.23) per share of common stock. This represents an immediate increase
in net tangible book value per share of $0.57 to our existing stockholders and an immediate dilution in net tangible book value per share of $4.27 to new investors purchasing common stock in this offering. The following table illustrates this
dilution on a per share basis to new investors participating in this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book deficit per share as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in as adjusted net tangible book value per share attributable to new investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book deficit per share after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes, for illustrative purposes, that an aggregate of 16,447,368 shares of our common stock are sold at a
price of $3.04 per share, the last reported sale price of our common stock on the Nasdaq Global Market on February&nbsp;23, 2018, for aggregate gross proceeds of $50.0&nbsp;million. The shares sold in this offering, if any, will be sold from time to
time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $3.04 per share shown in the table above, assuming all of our common stock in the aggregate amount of
$50.0&nbsp;million during the term of the sales agreement with Cantor Fitzgerald is sold at that price, would result in an increase in the dilution in net tangible book value per share to new investors in this offering to $5.31 per share, after
deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $3.04 per share shown in the table above, assuming all of our
common stock in the aggregate amount of $50.0&nbsp;million during the term of the sales agreement with Cantor Fitzgerald is sold at that price, would result in a decrease in the dilution in net tangible book value per share to new investors in this
offering to $3.20 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only and may differ based on the actual offering price and the actual number of
shares offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 119,053,414 shares of our common stock outstanding as of
December&nbsp;31, 2017 and exclude: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">7,089,440 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $9.33 per share as of December&nbsp;31, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,135,216 shares of common stock issuable upon the settlement of outstanding restricted stock units as of December&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,267,972 shares of common stock issued on January&nbsp;18, 2018 in exchange for $3,157,251 of our 9.75% senior convertible notes due 2019 at a conversion price of $2.49 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,011,185 shares of common stock issuable, as of the date of this prospectus supplement, upon the conversion of our 9.75% and 8.75% senior convertible notes due 2019 at a conversion price of the greater of (i)&nbsp;the
average of the volume weighted average price per share of our common stock for the three trading day period immediately preceding the date of any election by the holder of the notes to convert principal amounts of such notes and (ii) $3.25 per
share, subject to adjustment under certain circumstances; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,596,118 shares of common stock issuable upon the conversion of our 5.75% senior convertible notes due 2021 at a conversion price of approximately $5.15 per share as of December&nbsp;31, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">246,205 shares of common stock issuable under our employee stock purchase plan as of December&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">31,856 shares of common stock issuable upon the exercise of outstanding warrants at an exercise price of $13.05 per share as of December&nbsp;31, 2017; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,509,343 shares of common stock available for future grant under our 2013 equity incentive plan as of December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options or warrants are exercised or outstanding restricted units are settled, investors purchasing shares in this offering
could experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that
additional capital is raised through the sale of equity or equity-based securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_7"></A>PLAN OF DISTRIBUTION </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales Agreement with Cantor Fitzgerald, under which
from time to time we may issue and sell shares of our common stock having an aggregate gross sales price of up to $50.0&nbsp;million through Cantor Fitzgerald acting as agent. Sales of the shares of common stock, if any, may be made on The Nasdaq
Global Market at market prices and such other sales as agreed upon by us and Cantor Fitzgerald. We will file the sales agreement as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which is incorporated by
reference in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the sales agreement, Cantor
Fitzgerald may offer and sell shares of our common stock by any method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act. We may instruct Cantor Fitzgerald not to
sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or Cantor Fitzgerald may suspend or terminate the offering of our common stock upon notice and subject to other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Cantor Fitzgerald commissions, in cash, for its services in acting as sales agent in the sale of our common stock. Cantor Fitzgerald will be
entitled to a commission of up to 3.0% of the gross sales price per share sold under the sales agreement. Because there is no minimum offering amount required as a condition to this offering, the actual total public offering amount, commissions and
proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse a portion of Cantor Fitzgerald&#146;s expenses, including legal fees, in connection with this offering up to a maximum of $50,000. We estimate that the total
expenses for the offering, excluding commissions and expense reimbursement payable to Cantor Fitzgerald under the terms of the sales agreement, will be approximately $100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement for sales of shares of our common stock will occur on the second trading day following the date on which any sales are made (or such earlier day as
is industry practice for <FONT STYLE="white-space:nowrap">regular-way</FONT> trading), or on some other date that is agreed upon by us and Cantor Fitzgerald in connection with a particular transaction, in return for payment of the net proceeds to
us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by
such other means as we and Cantor Fitzgerald may agree upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will act as our sales agent and use commercially reasonable efforts,
consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The Nasdaq Global Market. In connection with the sale of the common stock on our behalf, Cantor Fitzgerald will be
deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to
Cantor Fitzgerald against certain civil liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of shares of our common stock pursuant
to the sales agreement will terminate upon the earlier of (1)&nbsp;the sale of all shares of our common stock subject to the sales agreement, or (2)&nbsp;termination of the sales agreement as permitted therein. We and Cantor Fitzgerald may each
terminate the sales agreement at any time upon ten days&#146; prior notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald and its affiliates may in the future provide various
investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, Cantor Fitzgerald will not engage in any market
making activities involving our common stock while the offering is ongoing under this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the
accompanying prospectus in electronic format may be made available on a website maintained by Cantor Fitzgerald and Cantor Fitzgerald may distribute this prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_8"></A>LEGAL MATTERS </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the common stock offered by this prospectus supplement will be passed upon for us by Cooley LLP, San Diego, California. Cantor
Fitzgerald&nbsp;
&amp; Co. is being represented in connection with this offering by Goodwin Procter LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_9"></A>EXPERTS
 </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements incorporated in this prospectus supplement by reference from our Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2017, and the effectiveness of our internal control over financial reporting have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered
public accounting firm, as stated in their reports, which are incorporated herein by reference (which reports (1)&nbsp;express an unqualified opinion on the consolidated financial statements and includes an explanatory paragraph relating to our
ability to continue as a going concern and (2)&nbsp;express an unqualified opinion on the effectiveness of internal control over financial reporting). Such consolidated financial statements have been so incorporated in reliance upon the reports of
such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_10"></A>WHERE YOU CAN FIND MORE
INFORMATION </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with
respect to the shares of common stock we are offering under this prospectus supplement. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the
registration statement. For further information with respect to us and the securities we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration
statement. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other material we file with the SEC, at the SEC&#146;s Public Reference
Room at 100 F Street, NE, Washington, D.C. 20549. Please call the SEC at 1.800.SEC.0330 for more information on the Public Reference Room. The SEC maintains an Internet site that contains reports, proxy and information statements, and other
information regarding issuers that file electronically with the SEC, including us. The SEC&#146;s Internet site can be found at www.sec.gov. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom502389_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered part of this prospectus supplement and the accompanying prospectus. Later information filed with the SEC will update and
supersede this information. The SEC&#146;s Internet site can be found at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference the documents listed below and any
future filings made with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement until the termination of the offering of the shares covered by this prospectus supplement (other than
Current Reports furnished under Item 2.02 or Item 7.01 of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and exhibits filed on such form that are related to such items): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, filed with the SEC on February&nbsp;27, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information specifically incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016 from our Definitive Proxy Statement on
Schedule 14A for our 2017 Annual Meeting of Stockholders, filed with the SEC on April&nbsp;7, 2017; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on January&nbsp;19, 2018; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form <FONT STYLE="white-space:nowrap">8-A,</FONT> filed with the SEC on July&nbsp;23, 2004, including all amendments and reports filed for
the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the
following address or telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MannKind Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30930 Russell
Ranch Road, Suite 301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Westlake Village, CA 91362 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(818) <FONT STYLE="white-space:nowrap">661-5000</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or
superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 </B></P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g502389g38c99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PREFERRED STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DEBT SECURITIES </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may sell up to an aggregate of $500,000,000 of our common stock, preferred stock, warrants or debt securities, individually or in units. We will specify in any accompanying prospectus supplement the terms of any offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The NASDAQ Global Market and on the Tel Aviv Stock Exchange under the trading symbol &#147;MNKD.&#148; The
applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The NASDAQ Global Market, Tel Aviv Stock Exchange or other securities exchange of the securities covered by the prospectus supplement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 25134 Rye Canyon Loop Suite 300, Valencia, California 91355, and our telephone number at that
address is (661)&nbsp;775-5300. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and any prospectus supplement carefully before you invest. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE
HEADING &#147;<A HREF="#rom473688_2">RISK FACTORS</A>&#148; ON PAGE 2 OF THIS PROSPECTUS AS WELL AS THOSE CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND UNDER SIMILAR HEADINGS IN THE OTHER DOCUMENTS
THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to offer or sell any securities unless
accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold directly by us to investors, through agents designated from time to
time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#147;Plan of Distribution&#148; in this prospectus and in the applicable
prospectus supplement. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and
over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this
Prospectus is April&nbsp;27, 2016. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_1">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_3">THE SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_4">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_10">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom502389_15">INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with information different from the information contained in or
incorporated by reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. No dealer, salesperson or other person is authorized to give any information or
to represent anything not contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only
the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is
accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus,
any applicable prospectus supplement or any related free writing prospectus, or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, using a
&#147;shelf&#148; registration process. Under this shelf registration process, we may sell common stock, preferred stock, warrants or debt securities in one or more offerings up to a total dollar amount of $500,000,000. This prospectus provides you
with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of those
securities. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may also add, update or change in the prospectus supplement (and in any related free
writing prospectus that we may authorize to be provided to you) any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to carefully read this prospectus, any
applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation by
Reference&#148; before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AFREZZA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
MedTone<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Dreamboat&#153; and Technosphere<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks in the United States. We have also applied for and have registered
company trademarks in other jurisdictions, including Europe and Japan. This document also contains trademarks and service marks of other companies that are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_1"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary highlights information contained elsewhere in this prospectus or incorporated by reference herein and does not
contain all the information that may be important to purchasers of our securities. You should carefully read this prospectus, all documents incorporated by reference, any prospectus supplement and any related free writing prospectus, and the
additional information described under the caption &#147;Where You Can Find More Information,&#148; beginning on page&nbsp;26, before buying any of the securities being offered. References in this prospectus to &#147;MannKind,&#148; the
&#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MannKind Corporation and its subsidiaries, on a consolidated basis, unless the context requires otherwise. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MannKind Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for
diseases such as diabetes. Our only approved product, AFREZZA, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration on June&nbsp;27, 2014 to improve glycemic control in adult patients with diabetes. AFREZZA
became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, in the United States in 2012, approximately 29.1&nbsp;million people had diabetes. Globally, the
International Diabetes Federation has estimated that approximately 415.0&nbsp;million people had diabetes in 2015 and approximately 642.0&nbsp;million people will have diabetes by 2040. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AFREZZA is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of
a dry formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, AFREZZA dissolves rapidly upon inhalation to the lung and delivers insulin quickly to the bloodstream. Peak insulin levels are
achieved within 12&#150;15 minutes of administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AFREZZA utilizes our proprietary Technosphere formulation technology; however, the
application of this technology is not limited to insulin delivery. We believe it represents a versatile drug delivery platform that may allow the oral inhalation of a wide range of therapeutics. We have successfully prepared Technosphere
formulations of anionic and cationic drugs, hydrophobic and hydrophilic drugs, proteins, peptides, and small molecules. Technosphere powders are based on our proprietary excipient, FDKP, which is a pH-sensitive organic molecule that self-assembles
into small particles under acidic conditions. Certain drugs, such as insulin, can be loaded onto these particles by combining a solution of the drug with a suspension of Technosphere material, which is then dried to powder form. The resulting powder
has a consistent and narrow range of particle sizes with good aerodynamic properties that enable them to fly efficiently deep into the lungs. Technosphere powders dissolve extremely fast after inhalation when the particles contact the moist lung
surface with its neutral pH, releasing the drug molecules to diffuse across a thin layer of cells into the arterial circulation, bypassing the liver to provide excellent systemic exposure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also created an innovative line of breath-powered, dry powder inhalers. Our inhalers are easy to use, cost-effective and can be
produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. Both the reusable and single use inhaler formats use the same internal air-flow design. Being breath-powered, our inhalers require only the patient&#146;s
inhalation effort to deliver the powder. Patients are not required to activate the inhaler prior to use and no activation step with inhalation is required. To administer the inhalation powder, a patient loads a cartridge into our inhaler and inhales
through the mouthpiece. Upon inhalation, the dry powder is lifted out of the cartridge and broken (or de-agglomerated) into small particles. The inhalers are engineered to produce an aggressive airstream to de-agglomerate the powder while keeping
the powder moving slowly. This slow-moving powder effectively navigates the patient&#146;s airways for delivery into the lung with minimal deposition at the back of the throat. Our inhalers show very little change in performance over a wide range of
inhalation efforts and produce high bioavailability. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our securities involves a high degree of risk. Prior to making a decision about investing in our securities, you should
carefully consider the specific risk factors discussed in the sections entitled &#147;Risk Factors&#148; contained in any applicable prospectus supplement and our filings with the SEC, which are incorporated by reference in this prospectus, together
with all of the other information contained in this prospectus, any applicable prospectus supplement or free writing prospectus, or incorporated by reference in this prospectus. These risks and uncertainties are not the only risks and uncertainties
we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any prospectus supplement or any
additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part
of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_3"></A>THE SECURITIES WE MAY OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock, preferred stock, various series of debt securities and/or warrants to purchase any of these
securities, with a total value of up to $500,000,000, from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general description of the
securities we may offer. Each time we offer a type or series of securities, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">designation or classification; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">aggregate principal amount or aggregate offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maturity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">original issue discount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rates and times of payment of interest, dividends or other payments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption, conversion, exercise, exchange or sinking fund terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ranking; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictive covenants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting or other rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon
conversion or exchange. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement and any related free writing prospectus that we may authorize to be
provided to you also may add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and
described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This
prospectus may not be used to offer or sell securities unless it is accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the
securities directly to or through agents, underwriters or dealers. We, and our agents, dealers or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through agents or
underwriters, we will include in the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name of those agents or underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">applicable fees, discounts and commissions to be paid to them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">details regarding over-allotment options, if any; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the net proceeds to us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B><I>. </I>We may issue shares of our common
stock from time to time. Holders of our common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. Subject to any preferences of any of our preferred stock that may be outstanding, holders of our common stock
are entitled to dividends when and if declared by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock</I></B><I>. </I>We may issue shares of
our preferred stock from time to time, in one or more series. Our board of directors will determine the designations, voting powers, preferences and rights of the preferred stock, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences,
sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities. Conversion may be mandatory or at your
option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants</I></B><I>.</I> We may issue warrants for the purchase of common
stock, preferred stock and/or debt securities in one or more series, from time to time. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from
these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you)
related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the
terms of the warrants being offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration
statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if
applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities</I></B><I>.
</I>We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated
debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be
convertible into or exchangeable for our common stock or other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking
association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may
authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. Forms of indentures have been filed as exhibits to the registration statement
of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will
be incorporated by reference from reports that we file with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_4"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our ratio of earnings to fixed charges for the periods indicated (in millions): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2011</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio (deficiency) of earnings to fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(368.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(191.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(170.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(161.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of this table, &#147;earnings&#148; consists of pre-tax income (loss) from continuing
operations, plus fixed charges and amortization of capitalized interest, less interest capitalized. &#147;Fixed charges&#148; consist of interest expensed and capitalized related to indebtedness. For the fiscal years ended December&nbsp;31, 2015,
2014, 2013, 2012 and 2011, we had no earnings, and consequently earnings for these periods were insufficient to cover fixed charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement that are not
strictly historical in nature are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934,
as amended, or the Exchange Act. These forward-looking statements are subject to the &#147;safe harbor&#148; created by Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act and may include, but are not limited to,
statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully market, commercialize and achieve market acceptance for AFREZZA or any other product candidates or therapies that we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture sufficient quantities of AFREZZA and obtain insulin supply as needed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize our Technosphere drug delivery platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates for future performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and amount of our future recognition of deferred product sales from collaboration, product costs from collaboration and income from collaboration; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress or success of our research, development and clinical programs, including the application for and receipt of regulatory clearances and approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific studies and the conclusions we draw from them; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipated use of proceeds from the sale of securities under this prospectus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some
cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;goal,&#148; &#147;intends,&#148; &#147;may,&#148;
&#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; the negative of these words and words or similar expressions intended to identify forward-looking
statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying information and expectations are likely to change
over time. Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including,
but not limited to, those set forth under the heading &#147;Risk Factors&#148; in any applicable prospectus supplement or free writing prospectus and in our SEC filings. These forward-looking statements represent our estimates and assumptions only
as of the date of the document containing the applicable statement. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus, in the documents
incorporated by reference herein and in any prospectus supplement by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or
developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully consider the
risk factors discussed here or incorporated by reference, in addition to the other information set forth in this prospectus, any accompanying prospectus supplement or free writing prospectus and in the documents incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we
currently intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses, sales and marketing expenses,
general and administrative expenses, and other expenses associated with the commercialization of AFREZZA, any other product candidate we develop and our Technosphere drug delivery platform. We may also use a portion of the net proceeds to
in-license, invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions. As of the date of this prospectus, we cannot
specify with certainty all of the particular uses of the proceeds from the sale of securities under this prospectus. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from the sale of
securities under this prospectus as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 550,000,000 shares of common stock, $0.01 par value, and 10,000,000 shares of preferred stock, $0.01 par value. As of March&nbsp;31, 2016, we had a total of 120,861,315 shares of common stock that were authorized but unissued, and we
have currently reserved a significant number of these shares for future issuance pursuant to outstanding equity awards, our equity plans and convertible notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary description of our capital stock is based on the provisions of our certificate of incorporation and bylaws and the
applicable provisions of the Delaware General Corporation Law, or DGCL. This information is qualified entirely by reference to the applicable provisions of our certificate of incorporation, bylaws and the Delaware General Corporation Law. For
information on how to obtain copies of our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#147;Where You Can Find More Information&#148; and &#147;Incorporation by
Reference.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder
of our common stock is entitled to one vote for each share on all matters submitted to a vote of our stockholders, including the election of our directors. Under our certificate of incorporation and bylaws, our stockholders will not have cumulative
voting rights. Accordingly, the holders of a majority of our outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. In all other matters, an
action by our common stockholders requires the affirmative vote of the holders of a majority of our outstanding shares of common stock entitled to vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
preferences that may be applicable to any outstanding shares of our preferred stock, holders of our common stock are entitled to receive ratably any dividends our board of directors declares out of funds legally available for that purpose. Any
dividends on our common stock will be non-cumulative. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation, Dissolution or Winding Up </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we liquidate, dissolve or wind up, the holders of our common stock are entitled to share ratably in all assets legally available for
distribution to our stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any outstanding shares of our preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has no preemptive, conversion or subscription rights. There are no redemption or sinking fund provisions applicable to our
common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding shares of our of preferred stock, which we may designate and issue
in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such
stockholder action is required by applicable law or NASDAQ rules), to designate and issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to
fix the designations, voting powers, preferences </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and rights of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereof, and to increase or decrease the number of shares of any such series, but not
below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of the
preferred stock of each series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a
part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred
stock. This description will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title and stated value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares we are offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the liquidation preference per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dividend rate, period and payment date and method of calculation for dividends, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether dividends, if any, will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the procedures for any auction and remarketing, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for a sinking fund, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any listing of the preferred stock on any securities exchange or market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting rights, if any, of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preemptive rights, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on transfer, sale or other assignment, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether interests in the preferred stock will be represented by depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our
affairs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue shares of preferred stock under this prospectus, the shares will be fully-paid and non-assessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an
amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change the powers, preferences or special
rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or
conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of
management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware takeover statute </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the DGCL, which regulates acquisitions of some Delaware corporations. In general, Section&nbsp;203
prohibits, with some exceptions, a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years following the date of the transaction in which the
person became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the board of directors of the corporation approved the business combination or the other transaction in which the person became an interested stockholder prior to the date of the business combination or other
transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction
commenced, excluding shares owned by persons who are directors and also officers of the corporation and shares issued under employee stock plans under which employee participants do not have the right to determine confidentially whether shares held
subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or subsequent to the date the person became an interested stockholder, the board of directors of the corporation approved the business combination and the stockholders of the corporation authorized the business
combination at an annual or special meeting of stockholders by the affirmative vote of at least 66-2/3% of the outstanding stock of the corporation not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL generally defines a &#147;business combination&#148; to include any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition of 10% or more of the corporation&#146;s assets or outstanding stock involving the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in general, any transaction that results in the issuance or transfer by the corporation of any of its stock to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as any person who, together with the person&#146;s affiliates and
associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL could depress our stock price and delay, discourage or prohibit transactions not approved in advance by our board
of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Certificate of incorporation and bylaw provisions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of deterring hostile takeovers or delaying
or preventing changes in our control or our management, including, but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our board of directors can issue up to 10,000,000 shares of preferred stock with any rights or preferences, including the right to approve or not approve an acquisition or other change in our control. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our certificate of incorporation and bylaws provide that all stockholder actions must be effected at a duly called meeting of holders and not by written consent. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our bylaws provide that special meetings of the stockholders may be called only by the Chairman of our board of directors, by our Chief Executive Officer, by our board of directors upon a resolution adopted by a
majority of the total number of authorized directors or, under certain limited circumstances, by the holders of at least 5% of our outstanding voting stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our bylaws provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide timely notice in writing
and also specify requirements as to the form and content of a stockholder&#146;s notice. These provisions may delay or preclude stockholders from bringing matters before a meeting of our stockholders or from making nominations for directors at a
meeting of stockholders, which could delay or deter takeover attempts or changes in our management. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our certificate of incorporation provides that, subject to the rights of the holders of any outstanding series of preferred stock, all vacancies, including newly created directorships, may, except as otherwise required
by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum. In addition, our certificate of incorporation provides that our board of directors may fix the number of directors by resolution.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our certificate of incorporation does not provide for cumulative voting for directors. The absence of cumulative voting may make it more difficult for stockholders who own an aggregate of less than a majority of our
voting stock to elect any directors to our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other provisions contained in our certificate of
incorporation and bylaws are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.
However, these provisions could delay or discourage transactions involving an actual or potential change in control of us or our management, including transactions in which our stockholders might otherwise receive a premium for their shares over
market price of our stock and may limit the ability of stockholders to remove our current management or approve transactions that our stockholders may deem to be in their best interests and, therefore, could adversely affect the price of our common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Shareowner Services. Its address is 480 Washington Boulevard, Jersey
City, New Jersey, 07310. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants from time to time under this prospectus for the purchase of common stock, preferred stock and/or debt securities in one
or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. While the terms summarized below will apply generally
to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The terms of any warrants offered under a prospectus supplement may differ from the terms
described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants issued under this prospectus may be issued under warrant agreements which we will enter into with a warrant
agent to be selected by us. We use the term &#147;warrant agreement&#148; to refer to any of these warrant agreements. We use the term &#147;warrant agent&#148; to refer to the warrant agent under any of these warrant agreements. Any warrant agent
will act solely as an agent of ours in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that
we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following
summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of
warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements and any free writing prospectus related to the particular series of warrants that we offer under this prospectus, as well as the complete
warrant agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including, to the extent
applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price and aggregate number of warrants offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency for which the warrants may be purchased; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on and after which the warrants and the related securities will be separately transferable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may
be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these
shares may be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any rights to redeem or call the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants will commence and expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the manner in which the warrant agreements and warrants may be modified; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of material United States federal income tax consequences of holding or exercising the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the securities issuable upon exercise of the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such
exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the
applicable indenture; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together
with specified information, and paying the required amount to the warrant agent, if applicable, in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and
in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_9"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time under this prospectus, in one or more series, as either senior or subordinated debt or as
senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in
more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also
are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt
securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an
exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of
which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of
material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the
applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue
discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be
described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of
the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit upon the aggregate principal amount that may be issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maturity date or dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the form of the debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the applicability of any guarantees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount
thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be
determined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest
payment dates or the method for determining such dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional
redemption provisions and the terms of those redemption provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to
purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be
advisable in connection with the marketing of debt securities of that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be
exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the
conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and
the manner of settlement for any conversion or exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to
such securities to be due and payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the terms and conditions upon which the election may be made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#147;United
States person&#148; for federal tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on transfer, sale or assignment of the debt securities of the series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or
advisable under applicable laws or regulations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or
exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include
provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of
our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of
default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid
extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any
payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not
constitute a default in the payment of principal or premium, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure
continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the
outstanding debt securities of the applicable series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if specified events of bankruptcy, insolvency or reorganization occur. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is
continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us,
the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to
appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90
days after the notice, request and offer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt
securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file
statements with the trustee regarding our compliance with specified covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with the provisions described above under &#147;Description of Debt Securities&#151;Consolidation, Merger or Sale;&#148; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence,
or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#147;Description of Debt Securities&#151;General&#148; to establish the form
of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written
consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of
debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extending the fixed maturity of any debt securities of any series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that
we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer or exchange of debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">replace stolen, lost or mutilated debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay principal of and premium and interest on any debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain paying agencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hold monies for payment in trust; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recover excess money held by the trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensate and indemnify the trustee; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appoint any successor trustee. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or
government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides
that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in
the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to
global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and
aggregate principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the
applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the
security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose
no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or
rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities
that may be selected for redemption and ending at the close of business on the day of the mailing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the
trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the
request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are
registered at the close of business on the regular record date for the interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular
series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain
holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the
applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination of Subordinated Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain of our other
indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue, nor does it limit us from issuing any other secured or unsecured debt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_10"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depository or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be
indirect holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be
represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating
institutions, which are referred to as participants, in turn hold beneficial interests in the securities on behalf of themselves or their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be
registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the
depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made
with one another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a
book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an
interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders, of the securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a
global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of
a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the
securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they
agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well
as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street
name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the
approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the
holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry
form or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it handles securities payments and notices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether it imposes fees or charges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would handle a request for the holders&#146; consent, if ever required; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these matters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a
security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued
in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its
nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#147;Special Situations When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or
its nominee, will be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an
account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the
security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular
security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities
through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations for Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#146;s rights relating to a global security will be governed
by the account rules of the investor&#146;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the
depositary that holds the global security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware
of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An investor cannot cause the securities to be registered in his or her name and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order
for the pledge to be effective. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#146;s interest in a global security. We and any applicable
trustee have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may
require you to do so as well. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and
other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate, and interests in it will be exchanged for physical
certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests
in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global security will terminate when the following special situations occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we notify any applicable trustee that we wish to terminate that global security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the
particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct
holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell our securities covered by this prospectus in any of three ways (or in any combination): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to or through underwriters or dealers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to one or more purchasers; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may distribute the securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">from time to time in one or more transactions at a fixed price or prices, which may be changed from time to time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to the prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities covered by this prospectus, we
will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms of the offering, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of any underwriters, dealers or agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts of securities underwritten or purchased by each of them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of securities and the proceeds we will receive from the sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any over-allotment options under which underwriters may purchase additional securities from us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any underwriting discounts or commissions or agency fees and other items constituting underwriters&#146; or agents&#146; compensation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the public offering price of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any discounts, commissions or concessions allowed or reallowed or paid to dealers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchange or market on which the securities may be listed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any public offering
price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. We may determine the price or other terms of the securities offered under this prospectus by use of an electronic auction. We will
describe how any auction will determine the price or any other terms, how potential investors may participate in the auction and the nature of the obligations of the underwriter, dealer or agent in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters or dealers may offer and sell the offered securities from time to time in one or more transactions, including negotiated
transactions, at a fixed public offering price or at varying prices determined at the time of sale. If underwriters or dealers are used in the sale of any securities, the securities will be acquired by the underwriters or dealers for their own
account and may be resold from time to time in one or more transactions described above. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters or dealers.
Generally, the underwriters&#146; or dealers&#146; obligations to purchase the securities will be subject to certain conditions precedent. The underwriters or dealers will be obligated to purchase all of the securities if they purchase any of the
securities, unless otherwise specified in the prospectus supplement. We may use underwriters with whom we have a material relationship. We will describe the nature of any such relationship in the prospectus supplement, naming the underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities through agents from time to time. The prospectus supplement will name any agent involved in the offer or sale of
the securities and any commissions we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment. We may authorize underwriters, dealers or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agents to solicit offers by certain purchasers to purchase the securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts
providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions we pay for solicitation
of these contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, dealers and underwriters may be entitled to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act, or to contribution with respect to payments which the agents, dealers or underwriters may be required to make in respect thereof. Agents, dealers and underwriters may be customers of, engage in
transactions with, or perform services for us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we may offer, other than common stock,
will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the
liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short
covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. This short sales position may involve either
&#147;covered&#148; short sales or &#147;naked&#148; short sales. Covered short sales are short sales made in an amount not greater than the underwriters&#146; over-allotment option to purchase additional securities in this offering described above.
The underwriters may close out any covered short position either by exercising their over-allotment option or by purchasing securities in the open market. To determine how they will close the covered short position, the underwriters will consider,
among other things, the price of securities available for purchase in the open market, as compared to the price at which they may purchase securities through the over-allotment option. Naked short sales are short sales in excess of the
over-allotment option. The underwriters must close out any naked short position by purchasing securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that, in the open market after
pricing, there may be downward pressure on the price of the securities that could adversely affect investors who purchase securities in this offering. Stabilizing transactions permit bids to purchase the underlying security for the purpose of fixing
the price of the security so long as the stabilizing bids do not exceed a specified maximum. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a
covering transaction to cover short positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on The NASDAQ Global Market may engage in
passive market making transactions in our common stock, preferred stock, warrants and debt securities, as applicable, on The NASDAQ Global Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the
offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display
its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase
limits are exceeded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, an underwriter&#146;s purchase to cover the syndicate short sales or to
stabilize the market price of our securities may have the effect of raising or maintaining the market price of our securities or preventing or mitigating a decline in the market price of our securities. As a result, the price of our securities may
be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the securities if it discourages resales of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters makes any representation or prediction as to the effect that the transactions described above may have on the
price of the securities. If such transactions are commenced, they may be discontinued without notice at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements incorporated into this prospectus by reference from our Annual Report on Form 10-K, and the
effectiveness of our internal control over financial reporting have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by reference (which
reports (1)&nbsp;express an unqualified opinion on the financial statements and includes an explanatory paragraph relating to our ability to continue as a going concern and (2)&nbsp;express an adverse opinion on the effectiveness of internal control
over financial reporting due to a material weakness). Such consolidated financial statements have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a reporting company and file annual, quarterly and current reports, proxy statements and other information with the SEC. We have filed
with the SEC a registration statement on Form S-3 under the Securities Act with respect to the securities we are offering under this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the
information set forth in the registration statement or the exhibits which are part of the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration
statement and the exhibits and schedules filed as a part of the registration statement. You may read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the
SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. Our SEC filings are also available at the SEC&#146;s website at www.sec.gov. We maintain a website at www.mannkindcorp.com. Information contained in our
website does not constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom502389_15"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information that we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this registration statement and prospectus the
documents listed below, and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial filing of the registration statement but prior to effectiveness of the registration
statement and after the date of this prospectus but prior to the termination of the offering of the securities covered by this prospectus (other than current reports or portions thereof furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K
and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, filed with the SEC on March&nbsp;15, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K, filed with the SEC on January&nbsp;8, 2016,&nbsp;January&nbsp;14, 2016 and February&nbsp;23, 2016; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form 8-A, filed with the SEC on July&nbsp;23, 2004, including all amendments and reports filed for the purpose of updating such description.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by
reference, including exhibits to these documents. You should direct any requests for documents to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MannKind Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25134 Rye
Canyon Loop Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Valencia, CA 91355 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(661) 775-5300 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance
with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also
is or is deemed to be incorporated by reference herein modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$50,000,000 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g502389g38c99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g502389g71g62.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>February 28, 2018 </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g502389g38c99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g502389g38c99.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4J5:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @
M('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @("!X;6QN
M<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @("!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @
M<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2 Q,"XP,2(*(" @>&UP
M.D-R96%T941A=&4](C(P,34M,#DM,#-4,#<Z-#(Z,#$M,#<Z,# B"B @('AM
M<#I-;V1I9GE$871E/2(R,#$U+3 Y+3 S5# W.C0R.C Q+3 W.C P(@H@("!X
M;7 Z0W)E871O<E1O;VP](D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RDB"B @('AM<#I-971A9&%T841A=&4](C(P,34M,#DM,#-4,#<Z-#(Z,#$M
M,#<Z,# B"B @(&1C.F9O<FUA=#TB87!P;&EC871I;VXO<&]S='-C<FEP="(*
M(" @>&UP5%!G.DY086=E<STB,2(*(" @>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD](D9A;'-E(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#TB1F%L<V4B"B @('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z0C<X0SA!
M0C(S1#4R134Q,4(X,C)%13%$1C)!,4,W,# B"B @('AM<$U-.DEN<W1A;F-E
M240](GAM<"YI:60Z0C<X0SA!0C(S1#4R134Q,4(X,C)%13%$1C)!,4,W,# B
M"B @('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HV,$1&1C<X
M-#9&-#)%,3$Q.$-%-44T-#)!045#030R1"(*(" @>&UP34TZ4F5N9&ET:6]N
M0VQA<W,](F1E9F%U;'0B/@H@(" \>&UP.E1H=6UB;F%I;',^"B @(" \<F1F
M.D%L=#X*(" @(" \<F1F.FQI"B @(" @('AM<$=);6<Z=VED=&@](C(U-B(*
M(" @(" @>&UP1TEM9SIH96EG:'0](C$R."(*(" @(" @>&UP1TEM9SIF;W)M
M870](DI014<B"B @(" @('AM<$=);6<Z:6UA9V4](B\Y:B\T04%14VM:2E)G
M04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP
M04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*
M;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,
M1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B
M1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F
M(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!9T%%04%W15(F(WA!.T%!25)!
M44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!
M:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1
M;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%
M:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+
M>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y6
M2T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS
M4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF
M(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"
M45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&
M34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW
M9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U45350
M4FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP
M86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T98
M67$W1EA9<3<F(WA!.T9867$W1EA9<3=&6%EQ<%A.>D9B=W1,2V%+4'9*.$)H
M:D=Y9VUN5S9Y36]L;49*1S-#9&M(:#@O1314-4M&6$EP9&EQ03%7>G5P678F
M(WA!.W).9W=455E&2G1Y-4EJ9G59<&%F<U!3;&5Q.5)L;4]11W@K;&I)2'!Z
M55!,2&U3>#AW-E=,-C%$4G5J=$)D,G-L4%9G=4EZ4U-'440F(WA!.V]Y;BMU
M4WHT5&IL4BM(;4\Y:&EY:5ES9C)(=51B2U<Q,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7@F(WA!.U8R2W5X5C)+=7A6,DMU
M>%8R2W!$8UA0,7I7;UE++W59;F]",DI88VXX2UIK0U!$1S)S;7EN,EDW66M7
M<F$Q36MZ45=X-$)$4C,V:VXF(WA!.W5"6'=Z27@T>%9L<FQ*0C(R=5@P56=-
M:BMQ;C=3="]!-4]7249!:U=4>%-*3$=S:4=Q=4%Y;C)/67!&3G)W.5!->2M5
M9GHX,4MW-3@F(WA!.V1),3930F)Q33=+<S@X4TUK=CA!>4Y9,5!G>#A-,VAW
M94YO=V8T;U@X9S98>'9#,5IJ+T1/=FTY>7I23S9D:7)S5F1I<G-69&ER<U8F
M(WA!.V1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F%K67)'>D1C9T5J-DU1<D1,5V-W,U5C>#,T34=B>$DF(WA!.W)V;6))
M5TMA05=:<7ES;UI45E=&45(S0GI#8C))86Q!.$XY37)J<7A:5#1H:E5(37E"
M<TY-:'5H9T-304)5;EE!6DY$36).4'$Q:$<F(WA!.W-P0RMM;%A*3D%/-7%F
M8DU+4G-T=S)$-#4X+RM:4# Y-3,Q5%=O2%!P>3-(*VEV,%!P46=2>$XW9D%G
M3V1N<$U0:#1O>%!C.&1Q.#,F(WA!.TAM36@S+V,K>&1-=6UU.4YT3'!H>&$T
M:&IL6F5L0S9H<69J;D=4:E5I2'-9;7AA2GE+6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1E@F(WA!.UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T971S,Q<S%T9%-1;F]P*T4K2VYP;6)'5FDR:VEK,C!$56%J-FY+9'AV0U0F
M(WA!.R]W05)Y;DQ$<7EG96EB6$YN8EA+:%IK1&=D1#!)*U)'5E)K4GE::U=P
M,C)L,DYU+T]/3#1X,%EK:VHU5G=N25-O:4AL4#4O9FU.*VDF(WA!.V1-4&QF
M5'!0.7E/;W@Q=G!&3SA6<S(S1&(Y<5AP+W$O35IT=7ED2'AY.%-8,&IL-R]W
M0FIQ93%D6G=2-$(Y579U94)E5CE#=4YE.'<F(WA!.S9F;SA!4'%8<S921F@K
M>6A.6&8U2V=,6C!'9DM-8T1).4$X+W X6&E4164X=G1U3TY)-#%J46-544)6
M561G3F=--%EM,W0Q,DMU>%8F(WA!.S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W!8<C%H-CA(<GAJ
M.35%3G@T<B\F(WA!.T%'6F)I;E)P:$U-8E9M4F=Y;6I+86=J<U)M53%S=#!Y
M+U<X='<S4U9D<$8Y+T@V8W<U=V]T,%1A5BME9D]&:#53.'583W(S6D1-9S0F
M(WA!.U=K0DY$3$]W4$)".3%4-$%%-6)P9$]C,'A%9F=.3W!Z:D9!>4PT-3%N
M5C<O049J5DQR5DY1;$TQ-61Y1U=A43=B;G-",D%'=TA96C(F(WA!.V501TE2
M15DX9SAB;'E'8VI).'DY,"\U>'DX:71$0DXU=79O-E!/1W0Y3%9U,&1A4WDO
M-TEJ9W9Y8GAZ43ES87%Z-%DK3'9U>4Y,43@F(WA!.U$Y950S2$Y%-W0R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5FDF(WA!.RMS-F0Y5FXY4TUF=4I$5F8X:SEX+U1-
M<DA/=S%31DQ.26QL:75X27)"26Q5=&---6]O:D<W1FEE;$U/45=%4C5V;E0X
M,W9Z0V9Z:#4F(WA!.VI0,5II3D8P+VQ&<#9B:FYV.&-X2&DY3G8X;6YV;E-D
M;C94=UEB+U5E9C9N;64P9%@T,#9(,&IL*W1,+T%-='9),3,U>#AY=S9E9UHF
M(WA!.TQ'2VMU;S-!+UEH0C-!4#AZ+UI8-RMG3U=A,U9$1$,K=E)Q,%=L3V%D
M9G=J;2MW3$MZ=&)+,&AS-U-.66)7,U)9;UEL*WEQ24M+0C@F(WA!.VAN2%-K
M6D=Z>DPR15EG0VAY5G-I;#)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8F(WA!.S)+=7A6,DMU>%94=6)E
M3S1H84=15E9H.4E066I$13!B45)B=S,X-R]!1'%U:6%E,VQ$5$IQ,SDV;V96
M-3$R2U%(9$E2-$=18G0O:R\F(WA!.S8R8C=S>E1C6CA36$EC=F8S=6PW53%8
M0DAW-#AZ>CEZ=S-4=$]V9%-V-$Q#>&EA93=U;E=+0T9E<DUX;T(O8FTY;DU2
M0DHU0C!%24<F(WA!.V-H16-Y*W9V>3,X:#)8:S-Y-TAP.&1*3#9A:W5O,U$O
M,UI+4C!&9C)%-DPY+U5N3T\Q;7%/860Y3VHR1VLP=W=W-%)Z-G-Q>D5C<#(F
M(WA!.TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W-C+TU$>G!:954F(WA!.U!,5GAQ
M<R]&-VHK-W-B66XK.6Y99D-U,UEF86(R1UI/:S!X>E1%4CAF8S0K<3%!=W=-
M:2M/=%,Q1S@Q2R]U3E%V6E1.9#-5:E-Z>70F(WA!.S%:;4Y4;EIW9TEG06-G
M.&)K;5IY36IZ3#)V.$%+6'E)*VDR-F$U<4-C3E9U1G)B4FXW5452+U4W9"]!
M8F5/85!8-G)J4$%0<$@R=E$F(WA!.V1N85!W>'AY*V\O63EZ,#(K5SAT9RMW
M:UAA4F9!+S(U;W!X;W4U:6)25U%3-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T8F(WA!.UA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3%*26MA3DI)=U)%0EHS63!!03-*2D])0W9K:C@S4% X;FTO>DTW,C=N.40F
M(WA!.U=02TA4;SDV158K3UEJ>&M)*S9G>G-/>CE*-$]09C9J>B]5.&PR:'$O
M1FYT.4DU9G):8BM24#56+W!/-6DX,#8Q1"]U3W0R-6%B8G4F(WA!.TYP-590
M.31W4%9%23(X5SEH=F@Y<6$O:$AH>"MR<C5/6C)8;V)0:5,U9% Q=F%T9#!Z
M,&U.,4-0,V)(.31O-T4Y+VMC,&U+9#=&,W,F(WA!.V]O3%,W-#)L,$A0.3 S
M=WE$,CAF;WEC-#)'35143&=144-$54AC15IH='IS5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F0F(WA!.VER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER>"\X035Y13@K='!7:THU6G-*3TXY<6EC<G@Q3S97=%-V2"]N
M<5%2+W%G*T\F(WA!.V)N<VI38V-V15!+4$PS+W-D4C)T<75#4$%/8W9U+V$X
M=2]+4#AS<"]/3W(O049I-U9O.4%S;4)V2F1X-G)D4D%H.%0K,&5W.7E-,G8F
M(WA!.V%'=$='3D0V>GDO5S9V<R]294Y+>CE!*S-Y9E9T=&)15S%V2&)7.&%X
M45%Q231O:T%65E9244M!3V=!>FMI4U1:97%!049"939Q-FPF(WA!.U=&5EE5
M25!C2$%L:6UQ864Q;F-51SA,-WAT+T0V37I)5#1G,'E&2G(U9G9V56A.<S4K
M3U!D4&1F-TUP>E)O,GIG53-Y;&TW1EA9<3<F(WA!.T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6'I&
M*V(O;#=5=%4O3V<V87163W(F(WA!.TY:<%IU,S)21S!A4DTS>58P8VY/<#=0
M>E)H<&5,*V)D=DTV+T1+97 T9C4Q4&]Z>3EO1VUE6#E(='1*,#))4E=L<6=6
M96Y*:BLP-VLF(WA!.V1763=K-7I78DQ,2DEY;'I,,%=,1D=%4D=024IJ;&)9
M-T971C9L*UDO:W%7.&LP<6$U96EU63)V0D=X9U-25TM63&IF:4@K1794:%@F
M(WA!.UET;6)$4C513TE$-&1F>#ER:E,Q34QQ+W@K3W9*6'-6;&<Q4TI/:G)+
M16(U5F\S-%E*8GA::FUY,TU.=61I<G-69&ER<U9D:7)S5F0F(WA!.VER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER1B]/
M4&LK4%8W>E-T87165F1A,$\T5S1T5TY!2EDF(WA!.W=W36QU>F1G-"MY9C)4
M.4]:5VXQ2$%*4E P>4@T3&HU<T%K67E(,5)0-$1*,4I+9VM&4U)5<6%62'1T
M55II=5$S:7)S5F52,U@U36$F(WA!.W)*9BMN1F17-'-1<VQR2&5S>FUD3$=C
M5$-33#9S63)J85=L>%%497%$=# S24\T:C)L141K8C4Q-3=D8C5B8W%D6E!1
M>4HU-V-R.'0F(WA!.SEQ*U!/,W!6:G!W5SAL=DA&2VMI0E0Q0SE/4G(T:DY:
M2V4Q3WA!,W1-<W%:3WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7@F
M(WA!.U8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8F(WA!.S)+=FQV
M.'10>DHX,R]W0T].1UA63EEU-W94<G$T*W%Y>%1Z3SA:37DK;7115%0T5V17
M>G%T8F]S9FA3-%EG4T%T-6I283-+8W-E2U(F(WA!.TU385I0*V98;FYZ2EEE
M86]D3C!056)M>6ES<DY:<C!7,&I2+TA.25%/9D5I=$8T52ME679:5VQH3$AX
M5$%.;EIY=3%.5FMJ35)G86\F(WA!.U=75RM3=GI),#-2=GEQ,%A7=DY7;WE3
M,TXR,7EI3R]+831M6DQM5F1H=51X541C-T1B,GI%,4]J;%!54VIJ1W=R,V-G
M-5=M,6=J9VHF(WA!.U!)960O954Q.'-F;E0U1CAX86Q(<'1R8U,R,3=/94YV
M2&12*VU*1R]L5FQ,<E4Y9U-+-51N-TYY-#0X4D9J>6)S4&%'3$I,:$(S6#8F
M(WA!.VXK8R]K1%1B+U5,0S=V6DDW=E13-E1X96I)4WIO-%%P1V%563%0,V(Y
M35ED;35P045$85-Z-U%W>$I"3S12;FMZ.#!02UAM*V%7,S F(WA!.VUE4F)Y
M1F9593!U13E/5&=#05=&0WEK5DDV2$LY5&]C;45826)-.5!R365884HS4V5B
M."]0>3-J<U1D3&544VM0=T9U:TQI56UL86@F(WA!.U<T:FHW:S5E3WES.3%4
M564P.$9887)Q=C5H-E(U9R],:E@Y6#AT6'-I6$9N87E&<4%X5'=38U-62DAA
M=$YI1%1)-#E(3$AN:D=9,DHF(WA!.RM"5%!64FYH;$M"-4%V4%!)6#5Y4S9*
M-4<Q3RLQ,BMM,6)6,W5Z2'!L<E!)>G4Q26Q*2DIQ5FI5;7!0,V(U<W18,F-*
M-5%)1&AJ5S<F(WA!.W(Y3#)J=UE42UHT<%AT.&U69FQ:;S,U:#9V9$1Z5C5Q
M,64W:',U,DTQ;&]Y4U!':FAT,60T=U%&:2]L5#ER<61V=%EM=7E9641W.&,F
M(WA!.U)F52]J<35E:6AM:V502512-5)1=C56*V%93$-Z.#$V<'%V;6$T,75Y
M<T1B=DHV;W5N3G-P85E54EIQ+V(R*W@T6DQ8641)=VI'06DF(WA!.U1F9'9Y
M-VU/:GEI4$A)>DUG4&9T>E1Y."]0,SAU8F%+,FM7-FYU4')+;'5-34I,4F=/
M52]E0FEN16YJ5VY7;2]C6E)(<VY/8C)!<'0F(WA!.VPR<&=&8C@R5'0U-SAP
M<C592&UC-FA'3D995D9Z4G%L<3 T8TMC*V1D=4Y+-6DO;&-N:65(6'%C;CAZ
M:C1/3R]3.'8X*R]N;&]'<F4F(WA!.U5R-D1Y,V8S9&AQ.&-K2FA9<5E89%!5
M2% P,U5T,C9G,$]B6%-D;'IH:T)M05EU=#%8855*67HT6G%8-UAO+S596#DW
M9BM19$9V3#(F(WA!.V0W;39M9S53>GES5V1J>EE66FIU8S%M=6=)-7!!8D,S
M63934FQI:51Z<#4U*V%0;G9Z8G%0;E=$>48U46Y.<&--55,V=6]M-%-.238F
M(WA!.V5O5D5G,U))-"]I67)V,3A..6QO9$QJ:FE/8DE,1')T8G%S:W-O=S1Z
M4C9L3$Y:.&DO;D(U36AG,6I2=&9U.6)K1'%T>EI1:659-S$F(WA!.V]40WAL
M16EE2G!55GDS2'%T3FU01$M):C4W9F4Q-4Y.<6-)-&]Z32],9C=T,W%,+T%*
M:396<&9L1W<Q,WI1<C908UAC640V9DQ'-&XF(WA!.SED9&Y226E/9$MJ66MD
M0TLU<6AO-51Y1T=0,4%D96IS>G%O>'AI8R]49E),+TQV-3-E44YD,4).4&AU
M<&)3-6Q92D%T,T@V87E-5%$F(WA!.T)80EI15#(U15I:;3=->EEX6D9J>6$X
M6&%/2$EA0C-2*W5F;7(U2S!05TQJ4TY4=D=G=F)74#%:5DUB;&5*45-!0F=+
M1FU"1D(T-5@F(WA!.VDP1UA*15-I3FDR6DYB:6A,:&MA2UAX9FYH*U@W43)-
M<S$Q3F%R<4940C8P3$%"5FQA17,U6&MQ:FMH-SE-<U!:;6%Y04QP<B]L2$0F
M(WA!.U%*3F-4=$8O4$@X=G18,5I.36=U<%E*<%A%9'9,8U)'3TM2,DY&0W15
M,'(R-6=9-65Z33!).%)#-"LP<TTU8TE/-F$K8V9Z33AO*U4F(WA!.UAJ:#%A
M-F(V,TMV3DQ30D1*3'<O;4E&06\X3U)&93)686926DTR.%)S,C9J5UDX6#%(
M9%0X;B]M;C5..#)80G1.3'5M4RM#;'A:,T,F(WA!.T=/57%/<%AQ<E4W.%=W
M-FI1-6-)=5$R-S!93F)J>6UO;F1,-R]W1%!$.'9B3#8V<W0U2S Y:DPV16QU
M<TPK;S!G3$M1;&5)3D]"<6$F(WA!.S K.%I:2'-Z3DMT=6)84'1(1$<W4$IV
M6'9Z<CAI84MT<TQM-&UL=6)M0TLU1G)"2'IK4T]:0DEN<59+;W)&5W)4;%@X
M34=,<S-,3S8F(WA!.T=W,E1L-U%X62M:,U4R+T]F>5IE959T5#%B5#<Q:VQS
M:S1M1U-)*W%K:W16:%EP.%%:4SE.>%5$=FMV-4YY:DE):V,P1'1$15E'45 F
M(WA!.TIH=FM4.#(W,U@O2R]M2%0Y9#%6;V1C*W%8:S%L9%)1;5 P65DW67-:
M43!#<CA33E9H5#1V1$TS5F1N:DAK:DM%9E19=C4K8F@V6%@F(WA!.VY,:FM*
M1W!59F=+-7-O+TMZ>DA:5U@U9C-7<F%X-6EB53=3,W4U4%8Q4S9-.59(1TU#
M365T5U$W;EE$>#)Z13$R17EZ0TU98TIR:TLF(WA!.R]1-5=J>6E/2&EL4&E&
M.'HK,61B9C@U0F9L>$YE:3).>&-1;U<T:39K9UE28CDY:7IG9DYC6F1K-7=,
M;V9.03=5=T4Q9C)-:3AY+VTF(WA!.U U4SAT>5=+87!E96U.4U@Q3%-73E=K
M:EI+:C1U85953#A1,WI'=S902FQV:$@P=51M,5=02%A%96%2,E U-R]!2F0S
M;7)P<'-D,TLF(WA!.VAK:T555C-*17E137A.0CA2*TI15#-:44UV;#)8;6I(
M:7(Y8E)(=$Q$2UA#0RMF3D8P,E=4>49Q*W-7-$EU3D@Q1W=M16<O6E-26E4F
M(WA!.W(O>4TY4$]I>50O9E)I955O>2]1-D1&12M!6D1N1U%+938S94XU;C W
M>C$U>613<7EY,DYN8F8V:&Q7;RMH64DO=GEJ1DAW<%DX6#DF(WA!.UDO:C5T
M*U=8:7AY-68V;T@R9G-613%45$0U4SAI-DUM:'=A=G(P-&Y.;3DU3D]K15EM
M,4=A3D8Y3T]71D=,>4IV>DY+1&5U4DU*94HF(WA!.VML>$=-3G)Q<BMK95)5
M6DDK2&IJ=VE5.39U-BMP138W6F5:8E@X,V9+9SAX4%EF<$(W=E0R14=N2W%*
M1D@Y84%62$%65'DV;F5U,V8F(WA!.TDT<%%/;6YW8U963&XW;5=E3U%A:4A(
M=S-9-64Y4&9)96HV6G%F-3EE848Q0S)J=6MT5&5Z=WAY<4A54T,U:FI$8U=Q
M1%):1%1-9E8F(WA!.UI*4C!K2TY86#-/4G!O0U=S;EDU6"MH53AQ,G1T868X
M-4AA;F(R<U-144MS,T=+3E%Q1&Q!<D=I:F)Q830U-44V244K6#-S<T%!,7,F
M(WA!.V=/-SE3:B]Z:EAO96I8.&5V6$8Y6E$S8W-:=#1O,FYJ5U1I:FE1<T%'
M0D$U8U)81#(Q;&Q(:$%.8S)(63)/2D5I4G5K2&M33DED0R\F(WA!.TUY1TUC
M66MS;5952%%"6&Q!*S1::V%O,U!#9E Y5%1P:%5C=TAD*W1)9DMN-5HV;C5L
M.&\V=G)U;E,X-W)42D973W=6871+<7!Z:S0F(WA!.VUV,F=#3TDW.5!$36I5
M83)/3$I'1755=7)I-F91;DQI;$U(8V1(=5@U2R]M65!.3VMN4SE4;')R*VYQ
M0DEZ9%HT4G-*9CE99$@K+W8F(WA!.VUH-U,P6&A3-&\O469S9#4R9')01FI5
M=G)(-'0U5#5&+W=#54,O37HO:DAA9CAN6C@R*W$O=F-0>"]1-GI49C-E8CAD
M-TQ026YL,U$F(WA!.W!V>44Q:3EM<TE*8G@W8E5::F-/:6U4;D%J;4EH>4]1
M-$=-155Z1#%785DQ:U%#875,;&%B1D@X;517.5-E8C-Z,VXO04-Q2%-L56XF
M(WA!.S9P*VUR=C%E=%!51G9&-F9T,$PU<S16*UIL,SA!*SAU=6YF-5=09'A&
M-EHK85=L95%O4'EG,#8T,#9',6IN271V,%900W%#5U)J5#$F(WA!.V540VI.
M.$)9=E@Y<G)V;7(P3U1-9%-22RMT=7DQ*U!%3D]#2S95.4,O2TPO04UL=&](
M+TU.+WAU,F$W=$0K+VPW,UEA3"LU:C=N:SDF(WA!.S=D=V564#A!;DEP-S=6
M,SE'>'5P0S8S3&XT4DAD5S526'%2.6Q:1'A0:%$K1V)E351L,%92-6HY0F16
M2U%X83(U8VHK<#9V-34O3D0F(WA!.WDW-50P=4LX95),*V5D,5=#>G0U54QS
M<#-,.39+0C-Z539847IY>7)L-74Q,4]S:&AJ6C-E3R]M1')-5W8O;4(U3C%0
M6$Q:<E!18C8F(WA!.S-T2G9Q.7=F9T5%;'DO<48R1D(X4S!,9C5.33-/:WAN
M2&AY4F=B;4-F=610<3AG;FUX>6QT06=C+V8X03)*<B]!335'5U!L83%S9$8F
M(WA!.V)466)71%9':UEG5W%O:DYB;$%1>F5M0E9E5D]*4'94=FQ063AS:$UU
M2RM(>C<R,W1I34)'2D9C5B]9;#AU:G<V-2ME,FQA9C5G:#DF(WA!.V-4,FQT
M2F91=E5C<%ET3D5P1&4S<4IU37-'430Y2DEW-WI8*VU96DU9;G$T:5%V8CE#
M="MC=6QE6$Q(.'E02W1I.71"639(=W0O<F,F(WA!.TU+3$1#<TPS:BMS94U9
M04AW,4IP9S=.>51L9VUB2FQV6'DR6'1'14DU<UEO0U R8S%8+VY)>E1F3$YI
M;6=T<%9V8E=U;U V;G<R:7 F(WA!.T=404%V06M29V)C=G-(-3!W9&IZ;DQI
M-&E34%!V6F1S4FA%4G)A6&PS251Y;D9B6&8U-EAI*V-&4C=S2R]O>#-60VAN
M16%#255F8F$F(WA!.TMP5W9T:S@U23!G.%!L-61Z2$-!9%EE4&XP.2LS-D56
M-3-T.4ES+WHT.'1P-6133T=F,7)-86I&86A65EI$3U9K1$)"44U94'0K,E$F
M(WA!.S!X;$Q35#0K5SE8-W8Q<W1304Y81&<U-U@K4&-P+VQ.-6(P4%=V>DTX
M,&Y6<DM+*U,Q:W5(:&AN55-2:&UU4T-X4G%Q,C-J:#=1>E0F(WA!.VAG:'=M
M<G(W:V%(1$-E9DIX0S90-E914WHV;"MA1W(R2&M4>3=P='9Q1VYM84<T,4,O
M86%105%U<T1T2$4P:&AJ54Y25D-2:SAF058F(WA!.T=#:$A"135P>6\Y0C@O
M9CEQ4DEY>GE'2TUE26-Y8CEY6"]L8F%L4$Y0;FE#-6MT-W534%1B,S%*<F16
M*W)V27-Q,6%)04MV2&PY;6<F(WA!.T=78398-W9'4EDY43DW2%%$.35K0F\W
M23<X;S0T5"M54&YL>7%M6DQE.$%A9S5"5%I(=C%O8V@R9U0K6G@K.&8W<&1"
M+VDR5"]/+S,F(WA!.TQ#-W0W<V9K>G V;U=&;S)U6$AR9V9:3&DS:CE/=C!C
M<5IM>$$O3DAV-$(Y-VE42B]+1"MU.50O041!,'HX=C1V>5AI;G-O<DY'3G8F
M(WA!.V)(5$QI3EEX33AW6D]8>$Q2;6-G=#9N,#%Z539395DV<6IF33,K4'5D
M<G$T66AP='%Q:%1Z1%<T<FTV.')F;"]$9CA!2F\U9G)5560F(WA!.U0X4F=.
M,D955C8Y3F@W6G1C4D%Y6E-03#4P-G9)1$M'15,X+VQB3G8K8VM.13!F5&),
M>39.3W-93%1E-&I0;U)R2%9&5TQI1'A!<E0F(WA!.W1834AS8DQ+4FYX16YL
M*VQZ3S)C8UEX:E%P-DYP4#5/955D3#!(5G1$9V$V97DQ:U)I-SE74D=C96E3
M54M%24%#0V$W9S5R8VYA3U,F(WA!.U4T>DY81C)74%$T-'=-0GEK,V(O04I0
M955R9GEJ9&56;S)U4G Q,V-,9%131U)05TUI.&%F2'=P>"]D:F%M03EO-41K
M1U1B:4%P4F\F(WA!.TU9>&Y(+T-53'%0-4=E4V(W4F1.,'%2<G5*9$M%:3)T
M,TA+9VY+4WET37E/5U)K235U4U!H,GEC3S%-<UI'5S-Q+W-A-3EM-'!1160F
M(WA!.R]4>55O9GE&.&M16$9N9'=3,S!6.5IY:61,=U1G>79)<D)K6GEY1595
M<G1X07=N=%A+45%A;SE+561M-&=19#=(5S O,%0X=3E",&(F(WA!.WI8<5!M
M93!E-$]P86U*5G56:V1414).27-R8U9#9VHT:T9..'@X=7-N4$=-6G)H:3,T
M.4Q#3U$U0CE28710>34P0S$X-E0K8C1N=40F(WA!.W%T=T=%:7,V;4@T:T-'
M:3AA.48O;7=Y,6MZ:4=08FA#>#!S0FM/5"M)="M2+W=!=3E".&U2,VME:U!C
M3W0V56%B-G<V=G9'1T,X94LF(WA!.W O3V-'<3%K.#%C5F),<'1,1$-#23E5
M1'!N-5$K5F1/=#EC9W0U3&]P<CA::79U8VE%:%-78CDS4D)X*S)E=&-S;C)H
M:VM9:S$V3U0F(WA!.T=':7AX-'%V,3@P>CAK*U$Y13AN5TYX6F%3,#=W,TUV
M<E-'-&188FQX0S=&5E1A9WER539Q95EG>39-.5!P;S12555Q:B]*+WEN0C4F
M(WA!.W)(;65Y939S9%%%,S%J,#=E4D5H-4@W631&1RM&.2M1<C-Y,#EO6D1J
M.$TP43%J431X:SA15TI/,'8X04HW>7!P=6QA,W!L=DID;3(F(WA!.S$U63%V
M:3AI1F=);5IL.4UH0E1E43E18UHY;UI*4VI),6-/4W<P3T]):T)F<C5P<G!0
M:U!23DLX;UA(;%,R86,V6F-X5'=Y33=Q6F4F(WA!.TYY1T0P64M"6#1J5&)+
M<VUQ;E!)36@K;U8Y:EI$5%)J:CA-9E1V.$%A9V)(.'%02TYR-5-N.'%T2$QC
M-EAC5$<U4')/1$MK<$-G3VHF(WA!.W%Q8U-/3S(S-%I:3%@U1&M'5&Q*:$A2
M67AJ.$]V4WAY2"]N1R]W1$PK3DI686)52FI*5&DW>E)G<%$Q*TAH16\S-F9%
M1&U393)C>"\F(WA!.VTO:C1U3DAS:D-/."]&-DHU93!/>3!(4G)44TQ)=3%R
M6G V8U)L25HV5DHK26=+3R]H;71Z6E1K:UI(;5A9-#A9:$522$E*6#4P+TPF
M(WA!.S-Y>C5W=&\T9%EG8C%982]6-W5&=44P65!50FE'0D(X1T)'5S9B5C5-
M2G5*8712<%E::%5G>$A2=BMC9&9)=6XS<3-6>DID86MS8F,F(WA!.VMT<F@P
M15(X3UEJ4D,S,S!0:&U::S=9>7E&0V]U2&HW2G=X3FTU93EM4&TO>40U83@R
M869&6F%T8FMI,W(Y5FUH4'!Y=S%!0C1':$8F(WA!.T118D5%93)996XQ8SA*
M=4HU=5IQ3DY$2TMK1TUE6"]Y0SAH84YQ55=O05A6+TQ!=V5'3SAK:F5.6%AC
M3GAJ:FDU52]Y<6I-<DXR=&TF(WA!.VY'=&@W;D=W.6PT<V-U3&-N>EI!+W=#
M6&5G=#4U5'IO6'50,'5G-'%N3F92<#9"="]S8V58,D0O041D8WAV>FLO0SA,
M8F@O8F)K2%,F(WA!.W=/6'A0-&YM4#4P85A(<5@U<RM5<E,T9V%A>75285%8
M4V=.47AY6&I+-$Q,,"M%-71/>F-N1' U:TAC6#EZ<F4P8V9&;GAI<D<Q+TXF
M(WA!.VPR:&9K1C5$,&I6;W146#8S95-14#9K3G9D4TDX2W5$5E1X4T]-='A0
M5&M4;4IL-U=Z5&IW-T0S3U9I-TQX46QX8FXS<'8U,B]+9GDF(WA!.VHU=W5%
M=3E3:FQG=FM526)Y,%I9-4=59$9F:W)Q,4]X2S%Y;E1A+TIH1E(U9'AB9%1O
M8V5B95A0=D-L-4PO2T1Y9#53=E1F,D5C,3$F(WA!.V8P2W@S5C(V>5!'1T9'
M0T)&:E%62&9J6#-W-FYT1$QM1DA995-.3F]-944S2&,Y-5)V;&8X=61!.'0V
M,7%/<V%E.7<Q,W%H63-);60F(WA!.U=18S5055!%0E9)*TDK3U%Z-GEE5TEJ
M2W%I,EED3$1(27EJ>FQZ4UA89GE-.&PV>')T>')-:VPU85A&,GAE-6ET6E93
M2U(S*S)X1$DF(WA!.S=$;BLQ4FAL,DQT5$Q#06IS44\Y;WED;31P>C0Y=U0S
M23-Y.2M54&Q(>3ER12MP85@Y66DK<W=V8E178E-"-$=H:T$U25%Y;#9654@F
M(WA!.S=68VAM-U%Y6DEI37$R,W9Q,EED1&IX>31O.55&<%@U1F539$QU3'5A
M,&4X53-L=&-78VE.2W)+<U8Q1UDS-#%3=%%R8D5K-5!*,G F(WA!.VQK0417
M>$(K5$1(,F)I:&18=4-0;6TK:R]L9C54,#=Y=&-E5GI#.35P3GI+,#AI6$Q"
M;D1S1D969$%H56IG2T5B-51K,3)35U%:3U4F(WA!.V@S3G-.2&IJ:CA/<FEX
M:3,O=T-C8U!Y*VEU;&YE5R]N:D1C:F)35%)I36HK56Q),&MP+W-S>7HR>FU)
M<C O3#ER:6IS:D-$92]U=&LF(WA!.S-M5#AR+TLO;4-B4W!,;U17-C9-;U-X
M:'175T].54)5:%-P5G1H=TA435A$<G-M35-R9FDU,C576%-1;5EK+W<X;%AZ
M>"M896<K8S0F(WA!.S=/4%8S=457>4QT1#E89%4S:T-H=5A*6"]K1U(P=7-N
M:'9H<F1/<#!S37=!;#!F+S)1/3TB+SX*(" @(#PO<F1F.D%L=#X*(" @/"]X
M;7 Z5&AU;6)N86EL<SX*(" @/&1C.G1I=&QE/@H@(" @/')D9CI!;'0^"B @
M(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG-3EZ.#4\+W)D9CIL
M:3X*(" @(#PO<F1F.D%L=#X*(" @/"]D8SIT:71L93X*(" @/'AM<%109SI-
M87A086=E4VEZ90H@(" @<W1$:6TZ=STB-C$R+C P,# P,"(*(" @('-T1&EM
M.F@](C<Y,BXP,# P,# B"B @("!S=$1I;3IU;FET/2)0;VEN=',B+SX*(" @
M/'AM<%109SI0;&%T94YA;65S/@H@(" @/')D9CI397$^"B @(" @/')D9CIL
M:3Y004Y43TY%(#(X-B!#/"]R9&8Z;&D^"B @(" \+W)D9CI397$^"B @(#PO
M>&UP5%!G.E!L871E3F%M97,^"B @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@
M(" @/')D9CI397$^"B @(" @/')D9CIL:3X*(" @(" @/')D9CI$97-C<FEP
M=&EO;@H@(" @(" @>&UP1SIG<F]U<$YA;64](D1E9F%U;'0@4W=A=&-H($=R
M;W5P(@H@(" @(" @>&UP1SIG<F]U<%1Y<&4](C B/@H@(" @(" \>&UP1SI#
M;VQO<F%N=',^"B @(" @(" \<F1F.E-E<3X*(" @(" @(" \<F1F.FQI"B @
M(" @(" @('AM<$<Z<W=A=&-H3F%M93TB4$%.5$].12 R.#8@0R(*(" @(" @
M(" @>&UP1SIT>7!E/2)34$]4(@H@(" @(" @("!X;7!'.G1I;G0](C$P,"XP
M,# P,# B"B @(" @(" @('AM<$<Z;6]D93TB0TU92R(*(" @(" @(" @>&UP
M1SIC>6%N/2(Q,# N,# P,# P(@H@(" @(" @("!X;7!'.FUA9V5N=&$](C8U
M+CDY.3DY-R(*(" @(" @(" @>&UP1SIY96QL;W<](C N,# P,# P(@H@(" @
M(" @("!X;7!'.F)L86-K/2(R+C P,# P,"(O/@H@(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" \+W)D9CIL:3X*(" @(#PO<F1F.E-E<3X*(" @/"]X;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" \>&UP34TZ2&ES=&]R>3X*(" @(#QR9&8Z
M4V5Q/@H@(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)S879E9"(*
M(" @(" @<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HV,$1&1C<X-#9&-#)%
M,3$Q.$-%-44T-#)!045#030R1"(*(" @(" @<W1%=G0Z=VAE;CTB,C Q,BTP
M,2TQ.50P,#HS,#HU,RTP-SHP,"(*(" @(" @<W1%=G0Z<V]F='=A<F5!9V5N
M=#TB061O8F4@26QL=7-T<F%T;W(@0U,U(@H@(" @("!S=$5V=#IC:&%N9V5D
M/2(O(B\^"B @(" @/')D9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](G-A=F5D
M(@H@(" @("!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.D(W.$,X04(R,T0U
M,D4U,3%".#(R144Q1$8R03%#-S P(@H@(" @("!S=$5V=#IW:&5N/2(R,#$U
M+3 Y+3 S5# W.C0R.C Q+3 W.C P(@H@(" @("!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@(" @("!S
M=$5V=#IC:&%N9V5D/2(O(B\^"B @(" \+W)D9CI397$^"B @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @/'AM<$U-.D1E<FEV961&<F]M"B @("!S=%)E9CII;G-T
M86YC94E$/2)X;7 N:6ED.D(V.$,X04(R,T0U,D4U,3%".#(R144Q1$8R03%#
M-S P(@H@(" @<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#I"-CA#.$%",C-$
M-3)%-3$Q0C@R,D5%,41&,D$Q0S<P,"(*(" @('-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#TB>&UP+F1I9#HV,$1&1C<X-#9&-#)%,3$Q.$-%-44T-#)!045#
M030R1"(*(" @('-T4F5F.G)E;F1I=&EO;D-L87-S/2)D969A=6QT(B\^"B @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "$
M 0D# 1$  A$! Q$!_\0 'P !  (" @,! 0            <("0H%!@,$"P$"
M_\0 /1   00" @$$ 0(# P@+    ! (#!08!!P ("1$2$Q05(2(*%C$7&",9
M)#(T04)8U1HH.5%A=)67H;CP_\0 '0$!  $% 0$!              8$!0<(
M"0," ?_$ $D1  $$ @$# @,%! 4'"@<   ,! @0%  8'$1(3%"$((C$5,D%1
M<18C0F$D,V)R@1=#4E:"D:$8-3B3EK&VT=/4)2938W22PO_:  P# 0 "$0,1
M #\ W^.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG5,V!,E8"*Y$+PXJ*
M:9(L1Z/13<?]CW9#BV<_KA4F;A"W7/7]H0;:U*S]EYA*:WTOABMEG3HAE<R*
M)?92]OWS._((^J(GXD>J)]Q'*OCY.\BB8OW$12N_T>OW6)_:=[K_ &43\U3.
MU8QA./3&/3&/]G_[_P"?^_E%GMG[QC'&,@'<6Y(O0#]4M=[<:!U!9;-$TBRV
MYY7QC:SL]KD6XVFSUD(<SAH>AV2PEB5"3EG%IQ5K%,5DHEO-<D9R3K<FH:$V
MS-FPJU%)>Q(9[&)!:G5]O#A"4L^-$:GS/LHD5CYP0(BK-B@F,8OJQ1@RXW>7
MH=:="F6*H.DERP5\N<Y>C*F7-*@8,F6Y?E;6RY3QP2F542'*/$>]/2ED%BS]
MR,Y),<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,CO:%SQ1ZF9*,Y1F3)4F.B$+]%8^\0A></J1GU]S8C+;
MI2DYQ[5J:0RK./EQGETIX'VC-&%W7PL12G5/;]VU4^5%_!7N5K$_%$57)]W*
M:6?TX7.3[Z_*S^\OX_[*=5_GTZ?CG6]#">RA-2SRU/G6"6EI,XEU67'WWD&.
M >YUU6<K7G/T\N9]V<_O=<5_5:LYJ]D)ULE"B(T<8  C8U.C6M5B%Z(U/9/Z
MSI[?@U$^B(B>5>G]'1ZKU<1[WN5?JJ]RM]U^J_=R1[59 *C R$_)>[(P#6%8
M9;]/E)(=6EH85GU_3Y'WEH1[L_M;3E3J_1M"LXM4*(6=)%&%T[B+[N7[K&HB
MN>]W\FM15Z?55Z-3W5,JC%:$;B.^C4^GXJJ^R(GZK_YY2J6WYL,\U9 $@+"B
M^_.60!(\ E"$8S^U+K\@,4^\OV^GR+PIIM2O52&6L9PE,_#K56,:-()\A_3Y
MB/*5BJOX]&B>QK4_+V543V5R^ZK87V,ESNK7(-/P:UK5Z?JKFJJ_]W\LG;4.
MX7[F2NO6%H=F<;860&6,G+3$FTSC&7VUL94K#)K2/\?.&L_"\REU26V/A]KD
M<O*)L!B2HJN='5R-(QZ]S@J[[JH[I[C5?E^;YFN5J*KN[VN$*:IU\1$1"=.K
M7)[(]$^J=/P<GU]O94Z]$3IG%]RM?0^U>IG9/7LZPR_'VC2.RP,9>2E21)!%
M2E2X:3;]WJE),1,# 2HCF<9PT4&RYZ9]OISWT*T/2[MJ5I&<YI8>Q5!?E545
MXEG!8<*]/=6' \@2)_$PCD_'++O=8"YTK:ZR0UKA3-?MA_,B+V%2$9X#)U]N
M\!V#,Q5^CQM7\,QC^![O%*=J>KQ>K=AS#DMMSK:Y"U&1DSG\O2=IUO)BDXU]
M8C7G5?*9)@-14K4I<GT>>=Q Q4M)DNR$ZXI67_B2XZ#IFXCN:L" H]L21.$$
M;>T,.V"]GVI%&U/E&$JF#- SY6M]28(FH*,B)B3X<N0C;CJ#Z>S.XUWJBQX1
M2D<KBS*HK'I62B.<O<0PT :$=WS.=Z<)RO4DE57.9S7/-A\<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC*@]F
MCGE256C?56&&03SO;_NJ>)(98]<X_IE3:!?1/K_HX<5Z?Z6?6<:B-J"F%Z?,
MX@Q]?R:UKG=/\5?[_GT3\DRRVKE[Q,_!&N=_BJHG_P#.=\ZZSS)].)@\KQ]N
M!D7\_%ZX]WT9)2BV'L8_KZ**R<WGT]?;E"<YS^_&.6[:8SASF2.GR21-^;_[
M@OD<W_\ 3QJGY]5_+*BL(C@*/\1N7V_LO^9%_P!_<G^&<QOV,,DM>DK#0MS$
M7) R9:&\94K(;2"!WEY3C]<H844V0[G^B&F5N*]$HSG'AK1ABLVH143S!($:
MK[)Y'*Q[4Z_FY&*UOYN<C4]U3/2Q8Y\9>WW['->[^ZG5%_W=>J_DB*OX90GF
M2,CN2_HR,,/V/#$#(7\,4V<><\G&?:R/D$@1.%9_I_CD$LL83Z^N<.*5Z9PE
M7+'L1ACJI#7JG<91C&U?JY_D8]>G]UK'.Z_R1/JJ96U[7.E,5/HSN<Y?R3M5
MO_%51/\ '/9\G^^8GKIT0[(WT\UH65E-<3VNJ:TIQ*2#+MLH%^EUY(;6<X42
MY&$3"[ 6RW^Y,5#2!*O:T.XM/YP]K1]JY)U.L$-SPAMHUK/5$7M'7U)&V$I7
MN^C$,P"16.7_ #QQ-3JYR(L:Y=V,.K<<[59$(UAC54FK@(JHCB6%J-T"*@T^
MKW"<=9+VI[H$!7KT:U534T_AU+Y*U?R"9J@KSOXO9>F=A5Z6%]V<L*7!+A;M
M'FK;]?;]@5VMO#,/9Q[VV9$MI.<)(<QG=KXJ:T,SC#UKVIYJB_JY0']/F1)*
M2*\HT7Z]KVRVO<WZ*X3%7W:F:6_"[9&A\F>B8Y?#;4-G%,SK\JK'4%@)ZI_I
M,=%<UJ_5&E>GT<N;X?.;6=&L<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC*R]DZZ\7$0EF'1E:8E]Z/D,IQZY
M0-(9:4*^O/\ NMM%,Y8SG_:X:WCDNU24UAI$1R]/,UI1?S>+JCVI^:N8[N_0
M:Y:K02JP94_@56N_1W3HOZ(J=/U<F5OH%S,HMD$FA\*=%S_FLH&G/I@R.=6G
M+S6/7.,8>;RE+XR\^F$OM(]WJVIQ*I590!V,5\=_1K_OA(O^;*B+VN_/M7JK
M7I^+57I[]%2UQCNCE1Z>Z?1[?])J_5/U3ZI_/,C0!T?.1@T@$ZT;&R8J7F5^
MF%M/COH_5*T*Q_M3G+;K3B?<A6%M.)PI*DXQ8098QGB(CAE"]6N3Z*U[5^J*
MG\_=KD7HJ='(O147).US2,1S51S'MZI^2HJ?BG_!47]%R'I;KY0),U9C.)B'
M2XO*W XLP= ?JK/JKXVC C5L)SG^C;+B&D8_:VVA.$XQ?0;/9!&@W> _1.B$
M,QZD]O9.JC(-'?JY%<OU5RKE"^MC.=W)WLZ^_:QR=O\ /HCFN5/T141/P3I[
M9)-5IM>I8*@( !(J'5)640M:GC#'$XSA*R27/5:_;ZJ^-I/L8:]Z_A:;]ZO6
MTS9\J>1"22*]6]48Q$[1C1?JC&)[)UZ)U7W<[HG<J]$RJ" 0&]HV].O3JJKU
M<Y4_%57_ +O9$_!$S1C\Z?D09[7[Q9T-J^92;H;0,U(B?D0",.QVP]J-H>B[
M!;&G&E98,A*TRHNK5$A'R-D(=L<X(41'V(-(_1GX<>+':5KKMEN(ZCV79HXG
M^(K>TM72JK3183FJG<.1+<C)DYB]',5L2.]C"Q2=W.OXB>4&[GL+=;J#H37-
M:D%9Y1N[A6=RB.#)F-5%[21XC>^)"<G<CD65(8]PI0T;+7\-=HZ5MO:G:.]R
M!',5?3^KB*T.=EO*6UW;9<D,-&C,N*QA#OP56 MSAJ&LJ<'45&Y=]B"FOELG
MQ:;$&#IE/K;7M]9>W#);A]>JI7U GO*]R)[M[ILF"@U7V<C"]O56+TO7PHZ\
M:;N5QL;F+Z.CIW1&DZ>RV%L5C!,:J^R]L.-.4B)U5JO%W=$>G7=JYSUSH!CC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,9QLQ%!3L6?#R+7S!2(KHA"/TQGV.IRGWH5G&?8ZVKT<9<QCU;=0A:
M?W)QSU <D8PCB7M()[7L7ZIU1?HJ?BU4]G)^**J?CGR]C2,<QR=6N145/U_+
M^:?5%_!<QJVVLG5"P2,!(8SET-[/PO\ MRE!@CG[Q2VO7UQ['V<I5E.,J^)S
MY&59][:\8RS"ECG1A21?0C?F;UZJ-Z>SQN_FUW5/HG5.CD]E3(L83@D<-WU:
MOLOX.;^#D_5/]R]4_#)OT)L;\2<FES#_ +8V3?RJ&?=5^T*3=S^X/.5?H@>1
M5Z?%C&<)0=Z>B?4MQ:8]LE5YQ^O WJ8+?W[43W(%J?UG\W"3Z_BH_P ?D:BU
M]=*['>!Z_*Y?D55^ZY?X?T<OT_M?KES>0++YF _SI^1K^ZOIC^[SJJ=^KOW>
MD&8.8?'$_'(ZVU46HB,F;,EUI6'@;!;'&S:U4G4?&^*VU89\8D0^%B\E;+_#
MCQ3^V=_^U%U&[]9UR2-PQ%9U#;73$:8$-6N^4D:$BCES6KU:]718SVO'(,C-
M;OB)Y2_8Z@_9BFD]FR[%'>UY!.Z%J:9ZN$>7U1>X<F:J$B0E3HYB)*DM<P@
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MIJZXVDD9[V&F5C #KW.&JH3TIS$4TIC%144[(S8ST1'@.4;D?EQNB?E5ZO\
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M.ONDY<0>K#P+1;0ZP)B2G!Z*))1D-](ZZ3]ACZU(SMJ*L$P[#PREI"CX](9
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MI)*6T>\CF>D"T<B2]J,4;I"A8\)6N1F7V!L'+>Y<I<A:3KVWOJJ^'97*+.E
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MHUW,26$9G,@"6[]9;C#R_=)^1=RUB=\.NIZ_7;+3RKL%5I()M/$LXI; 2PX
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ML 3/"YW8V0%JJR3%<_HY6-E1GFCN>C55B$5R(JHF;2;=KD7;M9N]:F/40+B
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MZ_;+$/E9V%@"[/9Y9D^'B&POO-!QWD7<M)U/CG7N'].OH^S**QA2+RZBO&2
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M.14OF@:5NNQ[EN/+.WTAZ UC3VD6EI##(RP(:36,K(Z+%(ULE@XM:%(B+)
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1QQC'&,<8QQC'&,<8QQC/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g502389g71g62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g502389g71g62.jpg
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M6[=>+//H([?^NJCD=R[60-F0TURX331D3'11)!VYT<M5_E^Y/]@-O\G\'?\
MIW_WC47GW0ABW[(6V.RHGOO&:9J,.K^[-[GL]_IA&.P>)"VZ;H@OAP_7:;GB
MS=B[1CXC95\JBY=;,!S]JJJ6.P^Y)\ ?,ZR?6AWK=_G;RD=I")28;8'LYZ<W
MH?MV] \*=,9(?Y;*VM_11>$UK_4L71#(FTQD?_U^,UW7SO&RL-.$Y ^WPL,!
M15.2M90O,V__ -:#R=]F\DD>/)W)U8)XS4"H4N=[$S:\PJEAYH8;CY_7R-D,
M)-(.@>U^EH$3,7G?O3$GB!%['CI^'QQPC7\5K7$EL9G G:3]L[GCQ\)=C-VK
M&/;ZOWW^2@[  >GC?[;:NFYF]-^+NO8O?,ZHFV\R>"\VOM&MJ38G$9C%8L-;
M*#S!1(N'+R8$+0D8I1D ++X7#?RU]$F[995LFW+!EB+5I5AMN-M_'C\'[ZH!
M[;[,HOUR[JH;SWB-M*-N#ZWE<:L3J":!A4T3ST%:3<DUT@'-\=2& \E\-DB;
MA! VL_3&MT2BTC,:[(&:VCJQ)J]044MWYCV ^0/\WS].WI_7MJ@D]$4?-@@*
M-32FZKF$=C UH&C8&55]$I$'CX@>W3:L184:8$/&8L>S;(I-VK-DBBW01332
M23UTTUQCV5,CD*!8T;URD6_4:EJ>L6]/B,+IO^^O!9HTK@ N4ZMH+^D6:\4X
M7["5&V_;7G8-6%:U@P5%5I7D&KP6OMINN-@T3 1)@MOIC.--E68 >/;J;:8V
MVQIMNGG.N,YQC./SGZVU>NWG$EVY:N2#P]JQ+8<;^=FE=V&_WU=7J5*BE*E6
MO50]RM>&.%3MXW6-5!V^HUW/WEUZ-/FFGS33YII\TT^::RP^X?I%M+K,C/DI
MS?8^T3G%ON!HWKFVXVT)2,W553&TT%G]50F/1M-U(9=;MC!'2372%1YNN?-M
MS<=KT.V='+$V5CS65%V'.1N!^D?,_,_0=R?M\M6L<,\9-*['U-/9C7FE7 */
MKI:K^0^='3P:9=<]UX8;IIRZ>V*5$JN0DDZDNS.F7UIR82Y(#(>+=.H'&#!=
M8O8DNGK5C'<_,GN3\S]/H/STVI)]);%FWM#Z)0KR.YXD9$?RWSQ(TK![DM6.
M*XRQ<FHJ\3;%8H@]UPLT=JPI=UB%QL<XU<-WUP''Q H)6%UND71:R+M&O.?U
M'LH^GS/Y_G6L>MZZA-0U_"ZLK:.#HC *\C(6'0V,"4LHC@<<C[! 8)'-M=MM
MU-]6[1NEINNNHJY<J?K<.5EG"JBN[6$]^Y\G7:_--/FFGS33YII\TU&JY><$
M[,EP&T(1:]D4'<$=CA"%H635Z<")NCT')$$3"L-FD2M&$6%!)6$9&D,&8^Y?
M1I.2Q,BZ+[Q60A6TDD[4TU7?]]4+3'EJBS-FWMV=>%[79+Z1Y+;S %;7:]QS
M8:\NBQ)7!W#EG/Z0X_'P4! :^YNJ^(RO#JOI7/J5A,<N&?VFN=JNLI9&<CI+
M)),_/S;_ %J_<[!0//\ *!V^Y]2?EOV V/VI7\?^9;D]$.^[9]'JLIRI:OJ6
MAI2J/Y]A\R0+!:EA4Y5#J!JQ8-A,1!.7EB%Z1BB[*T)JS:$8B_GEHNX^9/S0
M [F90VB_QK(YY$";[D_J/KM_^^ ?D-3NM3H^0^9MK1?R^\M#;?IWT@ZHOG>T
M.O.B+2$,C[3-D3;]XF7;$P M?^DCRS9GN_E\A8;+D1=401L4?&7!^52 J6#-
M6@!@7;LJC8 ?3P/4^O[DZEQZE^CE@\:5C6/GMQ2S 6%Z!W\^!5I)IO5<+C<(
M!0VR)@,":2B1@XL"T1#L[9E3@Z++B VZKW-9QZ0QV93HIC^;$\R5JU$!W9AL
M@W/WV]/]>F_?8[@ZY?&EG^//!,VICB][SJ8N6D18RX_0;K?I612%M7#2Y;'9
MC2*5>1I((W5D=E70='/!"<,ACA5MF.0+:#$)$Q)S&UP#8JU7<.V[;['LJKMO
MMOV^P_OYU+3GOT\O^$\,0KT4]+F]&<]4D;J#5S&:TKT7+SES7?8$E+-B-<RN
M-,I >9BH>A-X8.>KQNIVV)L[=,37_19/8L,C8I^"$/S\_/KJTJ.8JFY[^>W^
MO\_VU#>7>J'H(GQ]/O5ZR5H'RCR\.-0IKR9R*[B >5V;U0SD$T$,D7MH6-*6
MJQ>,!)1%L2(A'%ZS"QHHJ%8/)RBDO%@+%]/&KN1>8(/B/JWH/L/7;ZGOX]=>
M5HSV/OWF#AA/L_TNDS&96UUF;6+<-\3UC"8U$9D1@>RR^ )IPZ9"G,H0C,I<
MEARR<EE2T@R,A;6*.Q^DIFDR3 K-"@+;)X7]3$]OSMZ:D+SUZ!]9QKJ22Q[L
M.7Q5Q&H9RS_U_I2HZJKMBXB_+UR6O.8&,Y9Y8ATF9)E[*M3I:;QIU)_]EB+T
MZ6;RXV?CK&O(R,U$[O)"U:0-NWGFV!)VW&QW)'H/'?QYW.HQ=3^Y?45!VWU=
M$V,-J4I_P/DDA:,SK\<"*R%3G&Y;"LNKZTH.N;$M$9-% 5H3M!U9@<K<<=B8
M2/QH2^)XAD0/&U83))<:?V_/OZ?AU<$!V]-V['QN/+'Z; =M_.I<]9^VC;@?
MCGE\K?4!1G7H=?U(5O*M>78=AX$W$3>41P;DX7FK;;!HQ"XLSEB[T(P II%Y
M'()"T>QB.ZN4!1V1 VJ*G,Q /P@GXC\O3Y:K!["]0/7OAVM:*/W)9-5%>P.V
M,R%&O^&(=1L?>,N<H:48ZAH=*-S:+TM8DHMQQ.3,?%@(;*"LFB+EXPE,>>MI
M,2%NMQ[5P1&)VWY5&Y;Y[>?MOYU+;M+UJOOR]X5K>LN@K-CM_>L=XQ50RA%(
M]%8:-CE)[RW_ .+,B<C\'$,!1 ;!-=M T9;/47SZT)\U+/6F^\):.$135%0.
MQ(W"#Y^=O_8_;5=]0R6E_!"B1?2/4T.TZ7]G^R4R=B ZX/O,F9O5 >>.'.==
MIB?62*%HJZ,$7KY6P"PQM_M]A3!V1KJ.J. ,7/2AFU=WD.R_#&O]/_?W\#7=
M]H>@?L+Q_1%+S2Z^@0*/8G=1211BLN#*\I*!(CJ'K:210J"&2_60M1A&XW5Y
M"I_)Z^T@P$I,2P1N8U. 3K>:OQ)!F(:HJH2=A\*]RQW[[?3QM_?;OJ]'Q1\_
MH7Y]<RDH 4,@95U9,R@.:=>GF19H<-A[$/Q]K)8]7!%\DNY>:#(3&)(@H,R\
M6SJ>(G3TW::IMI8FDFU8[%COZ?RCY#\\_P!/35R7S5FGS33YII\TT^::A=Z(
M4[=G0'%]]4]SO.R];V].8R*'1F51\O\ Z^>T8-)9'BTPCX,YL['(B#$UA ^1
MPL81=DA@]F]D""Y$F.8Z.'J#55.Q!\['UU%WG"\F/*O*%><]G(9Z"SRUZKKU
M:)L35F<B7U94KD\C;Z/UQVQNQ*@B]L4SNQ8NW* H?NWMTP+9 &#%I@\1T;X>
MKM5(W)/P]SOV(_MN0?[?L-543#SO[Z]*ZSYPY1M, 4X)\Z*$C,$2EX<^>CLG
MZBZEFT8$M-#$YD,5B[^0 (8D7/\ ]X:'CYX:6)CY,97L*21R:G-Q(B-M7AE3
M<CNQW]-E4'Y?/^@'^[>:C@3X#4$-X^X$JJ<<J<\0@7_KTAZ L:NY#7<L#C%5
M%%9$C3%9VP#%6%-KGD[Q=X^)7#:,0&UV"(DMY@RVMLJ@I$M6K"=R2W<_+???
M]_E]COZ=O.J4O+'B>[Q]Y=/WG'*FF5,7[;%EV/6+>WK9A4AT%\9\X1^8D B8
MNM<V6QRZZ$ZLMYH(;&W<WQF6002SRULFV)M()5+)'65@-7LPV \@#<@$=V/G
MP.P![?;L-O(^9R=RC="7HAUO<X6EIV#LZIIK/.<.6YQ<4%FQ>KN:Z'!NR>DQ
MZX*R22,TW?2O0O1:AJ13B(Q"$&)&<EDHGT]EUIR&,129A""S0M\(&^X\G8]R
M?1?HJC;Z?+4=_1,/9=N.^'*L"^?'H99'FT)FLFMN9-!$(V;=#=D=$%#+E0K.
M;L$H*EIQ6@J3:%"QU$[9D9KV4RQK+)CI%P,6"BXR7C;54V 8\ZANP'?](^A]
M3]M_J>^I->BW+,]Z>N_S>M/NR!R6F>0X^;M8U-><*]$RNVPM)P:MHA"#=85+
M*$:@C9A&06_T053.A)<I%QFX.+PJ+BZ^KT@\,Q\O)YT_/S\_QWM5N4-MY.W?
MU\]SW]!_7ON?':M297[;_P#D!^B=>0*K*"E9W@SE%]E]":?6W3AM9DU!VR3
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1I\TT^::?--/FFGS33YIK_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
